Patent intelligence · TW
TW 202523278
Antibody drug conjugate platforms
Antibody drug conjugate platforms
Patent details — TW 202523278
- Jurisdiction
- TW
- Status
- granted
- Grant date
- Jun 16, 2025
- Expiration
- Jun 11, 2045
- Applicant
- BEIGENE LTD [KY]
- CPC classes
- A61K 31/ 16 A I, A61K 31/ 35 A I, A61K 31/ 40 A I, A61K 31/ 41 A I
Quick answer
TW 202523278 (Antibody drug conjugate platforms) is held by BEIGENE LTD [KY]. Status: granted. Granted Jun 16, 2025. Expires Jun 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEIGENE LTD [KY]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 16 A I, A61K 31/ 35 A I, A61K 31/ 40 A I, A61K 31/ 41 A I, A61K 31/ 095 A I, A61K 31/ 357 A I
More from BEIGENE LTD [KY]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
granted -
AU 2025242171
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
granted -
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
granted -
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
granted -
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
granted -
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
granted -
US 2025304535
KAT6 Inhibitors
granted -
US 2025290040
GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE
granted
Frequently asked questions
What is US patent 202523278?
TW 202523278 (Antibody drug conjugate platforms) is held by BEIGENE LTD [KY]. Status: granted. Granted Jun 16, 2025. Expires Jun 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns TW 202523278?
BEIGENE LTD [KY] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does TW 202523278 expire?
Our index shows an expiration date of Jun 11, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.